Finding safer and effective therapeutic approaches for cancer and autoimmune diseases.
T-One Therapeutics stems from the vision of a group of researchers aiming to exploit innovative RNA-based therapies to fight a wide spectrum of human pathologies, like cancer and autoimmune diseases.
The mission of T-One Therapeutics is to develop a novel pharmacological approach to specifically target RNA molecules transcribed from repetitive sequences of the human genome called LINE1 elements. We recently discovered that LINE1-derived RNAs accumulate in the nuclei of T lymphocytes with an impaired immune effector function, as dysfunctional T cells derived from tumor tissues
Importantly, we found that pharmacological inhibition of LINE1-derived RNAs through antisense oligonucleotides (ASOs) in TILs (Tumor Infiltrating Lymphocytes) reinvigorates the immune response against tumors. Thus, LINE1 represent a promising therapeutic target to modulate the immune response in several pathological contexts.